CCNB2 and cancer: Thus BUB1B, BUB1, TTK, CDC45, CDC6, CHECK1, CCNB1, CCNB2, and RRM2 may serve as the new prognostic biomarker and may also identify as a potential target for NSCLC cancer therapy.